首页> 外文期刊>Kidney and blood pressure research >Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat.
【24h】

Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat.

机译:卡托普利对一氧化氮缺乏型高血压大鼠心脏和肾脏损害以及代谢改变的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Chronic inhibition of nitric oxide (NO) synthesis is characterized by increased blood pressure accompanied with both cardiac hypertrophy as well as renal damage. We investigated whether the angiotensin-converting enzyme (ACE) inhibitor captopril can inhibit the cardiac hypertrophy and reverse the renal failure. We tested the influence of captopril on the nitrate-nitrite (NO(x)) in plasma and heart and kidney tissues. Oxidative stress, in terms of glutathione and thiobarbituric acid-reactive substances measured as malondialdehyde, was monitored examining their involvement in the cardioprotective and renoproptective actions. Three groups of Wistar rats were used: untreated group, and rats treated with the NO synthase inhibitor N(w)-nitro-L-arginine methyl ester (L-NAME) and L-NAME plus captopril (10 mg/kg/day). Systolic, diastolic and mean blood pressure (BPs, BPd and BPm respectively) was measured weekly in addition to the heart rate using rat-tail plethysmography. After 3 weeks, L-NAME significantly increased BPs, BPd and BPm. Captopril treatment reversed the increments in pressure back to normal values by the fourth week. ACE inhibition by captopril reverted the L-NAME-induced hypertrophy and inhibited the enzymatic indices of cardiac damage (glutamate oxaloacetate transaminase and lactate dehydrogenase) back to normal values. Furthermore, the NO synthesis inhibition produced renal damage as indicated by significant increase in creatinine. Captopril ameliorated the raised creatinine to normal. Chronic L-NAME treatment increased serum NO(x) levels but concomitant treatment with captopril was without effect.
机译:慢性抑制一氧化氮(NO)合成的特征是血压升高,并伴有心肌肥大和肾脏损害。我们调查了血管紧张素转换酶(ACE)抑制剂卡托普利是否可以抑制心脏肥大并逆转肾衰竭。我们测试了卡托普利对血浆,心脏和肾脏组织中硝酸盐-亚硝酸盐(NO(x))的影响。以谷胱甘肽和硫代巴比妥酸反应性物质(丙二醛)为单位,对氧化应激进行了监测,检查它们是否参与了心脏保护和再保护作用。使用三组Wistar大鼠:未治疗组和用NO合酶抑制剂N(w)-硝基-L-精氨酸甲酯(L-NAME)和L-NAME加卡托普利(10 mg / kg /天)治疗的大鼠。使用大鼠尾部体积描记法,除了测量心率外,还每周测量收缩压,舒张压和平均血压(分别为BPs,BPd和BPm)。 3周后,L-NAME显着增加BP,BPd和BPm。卡托普利治疗在第四周将压力增加恢复到正常值。卡托普利对ACE的抑制作用使L-NAME引起的肥大恢复,并将心脏损伤的酶学指标(谷氨酸草酰乙酸转氨酶和乳酸脱氢酶)抑制回正常值。此外,如肌酐的显着增加所表明的,NO合成抑制产生肾损害。卡托普利改善了肌酐升高至正常水平。慢性L-NAME治疗可增加血清NO(x)水平,但卡托普利的同时治疗无效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号